Laigo Bio, with CMM-PI Madelon Maurice as scientific founder, raises €11.5M seed financing to advance its SureTAC™ targeted protein degradation pipeline

These proceeds will support the advancement of the SureTAC™ oncology programs toward clinical development, the acceleration of discovery as well as development efforts across three SureTAC™ immunology candidate programs: addressing autoimmune-, inflammatory- indications and graft rejection.

See here for more information on Laigo Bio and our other entrepeneurs.